A Phase II study targeting amyloid-ß with 3APS in mild-to-moderate Alzheimer disease
Neurology Aisen et al.
67: 1757
Data Supplement
Two tables; one Word document.
Files in this Data Supplement:
E1
-
Table E-1. Most common adverse events (all causalities) in both the treated and placebo subjects over the course of the double-blind and open-label extension phases; Table E-2. Serious Adverse Events by Preferred Term (All Causalities); Word document.
